Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy

Research output: Contribution to journalArticlepeer-review

157 Scopus citations

Abstract

Multicomponent chemotherapy has increasingly become a strategy of great importance in clinical cancer treatments. However, this type of chemotherapy has not been demonstrated in nanoscale delivery vehicles where two cytotoxic agents can be packaged together, potentially leading to synergistic drug activities. Herein, we present the codelivery of doxorubicin and cisplatin via a single polymer-caged nanobin (PCN) and show that copackaging can yield strong synergy in the efficacy of these agents. Such a PCN comprises a doxorubicin-encapsulated liposomal core protected by a pH-responsive cisplatin prodrug-loaded polymer shell with tunable drug ratios and surface charge potentials. This dual-agent Pt-PCNDXR formulation dramatically enhances the overall cytotoxicity of each drug against cancer cells at reduced doses and exhibits higher synergy than combinations of either the free drugs or separately nano-packaged drugs. These results clearly indicate that the polymer-caged nanobin platform can offer new means for building synergy into combination chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)17130-17138
Number of pages9
JournalJournal of the American Chemical Society
Volume132
Issue number48
DOIs
StatePublished - Dec 8 2010

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Biochemistry
  • Colloid and Surface Chemistry

Fingerprint Dive into the research topics of 'Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy'. Together they form a unique fingerprint.

Cite this